SCHEMBL42032

SCHEMBL42032

COc1ccc(B(O)O)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
ENPP2 Q13822 2/20 0.50
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
HTT P42858 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29636771 1.00 CA1 (0.50) CA1CA2ENPP2HTR3EHTR3B
SCHEMBL18073529 0.83 HTR3E (0.43) CA1CA2HTR3EHTR3BHTR3A
SCHEMBL1960037 0.83 ENPP2 (0.50) CA1CA2ENPP2HTR3EHTR3B
SCHEMBL8696330 0.80 TRIM24 (0.57) CA1CA2ENPP2HTTGAA
SCHEMBL29957088 0.80 TRIM24 (0.57) CA1CA2ENPP2HTTGAA
SCHEMBL16335197 0.79 HPGD (0.37) CA1CA2ENPP2SMN1; SMN2MAPT
SCHEMBL29953230 0.79 HPGD (0.37) CA1CA2ENPP2SMN1; SMN2MAPT
SCHEMBL29496939 0.78 CA1 (0.58) CA1CA2ENPP2TUBB4ATUBB
SCHEMBL203357 0.78 CA1 (0.58) CA1CA2ENPP2TUBB4ATUBB
SCHEMBL15193542 0.78 ALDH1A1 (0.46) HTTGAASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-11793220-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2023-10-24 US claimed
US-20220264914-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-08-25 US claimed
US-20220225646-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-07-21 US claimed
US-20220225647-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-07-21 US claimed
CN-106636043-B Method for producing protease 广州立白企业集团有限公司 2020-04-07 CN claimed
CN-106636043-A Preparation method of protease 广州立白企业集团有限公司 2017-05-10 CN claimed
CN-105330642-A Selenophen compound INOR WUHAN PHARMACEUTICAL CO LTD 2016-02-17 CN claimed
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 US disclosed
US-12528801-B2 Substituted azacyles as TRPM8 modulators GIVAUDAN SA (CH) 2026-01-20 US disclosed
US-12497386-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2025-12-16 US disclosed
US-20250368605-A1 Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2025-12-04 US disclosed
WO-2000077010-A2 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 WO disclosed
WO-2000077001-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 WO disclosed
US-6107508-A SYNTHETIC INTERMEDIATES IN THE PREPARATION OF A SERIES OF BIOLOGICALLY IMPORTANT MOLECULES SUCH AS CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS DUPONT PHARMACEUTICALS COMPANY (US) 2000-08-22 US disclosed
WO-1999051568-A2 A CONVERGENT SYNTHESIS OF α-ARYL-β-KETONITRILES DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS TRPM8, TRPM7, TRPM5 CA1 739/4885CA2 184/4885ENPP2 4310/4885
US-20250368605-A1 Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof CYP19A1, ESR1, ESR2 CA1 1947/4885CA2 3145/4885ENPP2 1944/4885
US-12497386-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 CA1 3587/4885CA2 2407/4885ENPP2 604/4885
US-12528801-B2 Substituted azacyles as TRPM8 modulators TRPM8, TRPM7, TRPM4 CA1 785/4885CA2 240/4885ENPP2 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.